Terminated PHASE1/PHASE2 INTERVENTIONAL 8-arm NCT03288493

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P BCMA-101 in Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)

Sponsor: California Institute for Regenerative Medicine (CIRM)

Conditions Multiple Myeloma

Interventions P-BCMA-101 CAR-T cells Rimiducid

Updated 21 times since 2017 Last updated: Mar 26, 2024 Started: Sep 20, 2017 Primary completion: Apr 27, 2022 Completion: Apr 27, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Phase I portion of the study was completed. The phase II portion of the study was terminated early to focus on an Allogeneic BCMA CAR-T program.

Other terminated trials from California Institute for Regenerative Medicine (CIRM)

See all terminations from California Institute for Regenerative Medicine (CIRM)

Other Multiple Myeloma trials with similar outcome

Browse all Multiple Myeloma trials

A PHASE1/PHASE2 clinical study on Multiple Myeloma, this trial is terminated or withdrawn. The trial is conducted by California Institute for Regenerative Medicine (CIRM) and has accumulated 21 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

21 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2024 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Jul 2023 — Apr 2024 [monthly]

Terminated PHASE1_PHASE2
Jun 2022 — Jul 2023 [monthly]

Terminated PHASE1_PHASE2

Status: Active Not Recruiting → Terminated

▶ Show 16 earlier versions

May 2022 — Jun 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Feb 2022 — May 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Dec 2021 — Feb 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Oct 2021 — Dec 2021 [monthly]

Recruiting PHASE1_PHASE2
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE1_PHASE2
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2
Apr 2020 — Dec 2020 [monthly]

Recruiting PHASE1_PHASE2
Dec 2019 — Apr 2020 [monthly]

Recruiting PHASE1_PHASE2
Sep 2019 — Dec 2019 [monthly]

Recruiting PHASE1_PHASE2

Phase: PHASE1 → PHASE1_PHASE2
Apr 2019 — Sep 2019 [monthly]

Recruiting PHASE1
Dec 2018 — Apr 2019 [monthly]

Recruiting PHASE1
Sep 2018 — Dec 2018 [monthly]

Recruiting PHASE1
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE1
Mar 2018 — Jun 2018 [monthly]

Recruiting PHASE1
Feb 2018 — Mar 2018 [monthly]

Recruiting PHASE1
Oct 2017 — Feb 2018 [monthly]

Recruiting PHASE1

First recorded

Sep 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

California Institute for Regenerative Medicine (CIRM)
Poseida Therapeutics, Inc.

Data source: Poseida Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Chicago, United States , Davis, United States , Denver, United States , Detroit, United States , Gilbert, United States , Hackensack, United States , Houston, United States , Nashville, United States , Philadelphia, United States and 4 more locations